NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 59.32

+2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (316)	6/10/2010 9:31:07 AM
From: david nordic	Read Replies (2) of 507

whatisthetrend.net. Ovarian Cancer Treatment: A New Drug from Nektar Therapeutics Posted on 10 June 2010 6:19 am . Tags: Cancer, Ovarian Cancer, Ovarian Cancer Treatment Recent reports from American Society of Clinical Oncology said that there is a new drug from the Nektar Therapeutics that is very beneficial for ovarian cancer patient. This is indeed one of the advancement that we can see in the medicine industry. The results show that 48% of patient with advanced ovarian cancer gain benefits from the drug called NKTR-102 in the middle of the study. The drug was given to the patients in a dose of once every three weeks and lots of positive response was gathered. It is said that there are 23% of patients that was proven to show shrinkage in the size of their ovarian tumors while there are 38% who shows reduction in the number of the ovarian cancer biomarker which is the CA-125. According to the researchers, the overall total of the success rate in the women with ovarian cancer is 48%. On their study the patient who was given the NKTR-102 drug shows no progress with their disease. This is indeed a good thing and will surely give ovarian cancer enough hope to fight with their condition. The study result was presented in the American Society of Clinical Oncology in Chicago during the annual meeting last Sunday. The Nektar Therapeutics said that the study was based in the 68 patients with ovarian cancer. Dr. Ignace Vergote, head of obstetrics gynecology and gynecologic oncology at the Catholic University of Leuven, Belgium said that the result shows that NKTR-102 is very therapeutic with patients. This is one of the path where in women can take in order to battle against ovarian cancer. Statistics show that 230,000 women are diagnosed having ovarian cancer every year. This is a big population that the oncology doctors should deal with. From that percentage there are approximately 70% who die with advanced disease within five years. There is also a study being held whether the drug NKTR-102 can also benefit those patients with metastatic breast cancer or those that have colorectal cancer. There are still further studies about NKTR-102 according to Nektar Therapeutics.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next